Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug Ozempic.) Eli Lilly is hot on Novo Nordisk's heels with its new obesity drug Zepbound.
(NYSE: PFE) remains on the outside looking in with this big opportunity. But that doesn't have to be the case. Should Pfizer acquire Viking Therapeutics (NASDAQ: VKTX) to take on Lilly and Novo Nordisk in the obesity-drug market?
Let's first look at the potential downsides to Pfizer acquiring Viking. One especially stands out: Pfizer already has two weight-loss candidates in its pipeline -- danuglipron and PF-07976016. The latter only recently advanced into clinical testing, so it has a long way to go. Danuglipron, though, is farther along in development.
Source Fool.com
Pfizer Inc. Aktie
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
